@inproceedings{inproceedings, title  = {{Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis}},

 url = {{}},

 year = {{2013}},

 month = {{9}},

 author = {{Coleman R and Fossa S and Chodacki A and Wedel S and Bruland O and Staudacher K and Garcia-Vargas J and Sartor O}},

 volume = {{49}},

 journal = {{EUROPEAN JOURNAL OF CANCER}},

 pages = {{S688-S688}},

 note = {{Accessed on 2025/10/10}}}